ANDA 215415, held by Teva Pharmaceuticals. Lisdexamfetamine Dimesylate.
As of Nov 21, 2026, ANDA 215415 (Lisdexamfetamine Dimesylate), held by Teva Pharmaceuticals, was first approved by FDA on Aug 25, 2023, with 0 approved supplements and 0 published complete response letters.
Lisdexamfetamine dimesylate chewable tablets are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Moderate to severe binge eating disorder (BED) in adults. Limitations of Use: The use of lisdexamfetamine dimesylate chewable tablets is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage. Lisdexamfetamine dimesylate chewable tablets are not indicated or recommended for weight loss.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 25, 2023 | Original application | Approved | None posted |
| Lisdexamfetamine Dimesylate10MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate20MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate30MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate40MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate50MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate60MG · tablet, chewable;oral | Lisdexamfetamine Dimesylate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters